Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8217588rdf:typepubmed:Citationlld:pubmed
pubmed-article:8217588lifeskim:mentionsumls-concept:C0024299lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0596227lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0019638lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0019829lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0037995lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0751623lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0284965lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C1261322lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C1306673lld:lifeskim
pubmed-article:8217588lifeskim:mentionsumls-concept:C0015737lld:lifeskim
pubmed-article:8217588pubmed:issue5lld:pubmed
pubmed-article:8217588pubmed:dateCreated1993-12-7lld:pubmed
pubmed-article:8217588pubmed:abstractTextThe risks of second primary cancer were analysed in 2846 patients with Hodgkin's disease treated within the British National Lymphoma Investigation during 1970-87. The relative risk (RR) of leukaemia was significantly greater in women (RR = 30.1; 95% confidence limits (CL) 13.0-59.5) than in men (RR = 10.9; 95% CL 4.7-21.5), and showed a significant trend of greater risk with younger age at first treatment (P < 0.001). The relative risk of solid cancers was similar between the sexes, but again significantly greater at young than at older ages of first treatment (P < 0.01). Non-Hodgkin's lymphoma relative risks, although not related to sex or age, were significantly related to histology of the original Hodgkin's disease, and were greatest after lymphocyte predominant Hodgkin's disease (RR = 55.6; 95% CL 18.0-129.7). The relative risk of second cancers did not vary significantly according to whether or not splenectomy had been performed. Leukaemia risk was non-significantly greater after splenectomy than with no splenectomy, which accorded with previous evidence of a modest increased risk associated with this operation. If the greater relative risk of solid second cancers after treatment at young than at older ages persists with longer follow-up, the incidence rates of these second primaries in patients treated young for Hodgkin's disease will become very substantial as they age. This emphasises the need to maintain long-term follow-up surveillance of young Hodgkin's disease patients apparently cured of their disease, and to continue to develop new less carcinogenic treatment regimens.lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:languageenglld:pubmed
pubmed-article:8217588pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8217588pubmed:citationSubsetIMlld:pubmed
pubmed-article:8217588pubmed:statusMEDLINElld:pubmed
pubmed-article:8217588pubmed:monthNovlld:pubmed
pubmed-article:8217588pubmed:issn0007-0920lld:pubmed
pubmed-article:8217588pubmed:authorpubmed-author:SwerdlowA JAJlld:pubmed
pubmed-article:8217588pubmed:authorpubmed-author:DouglasA JAJlld:pubmed
pubmed-article:8217588pubmed:authorpubmed-author:MacLennanK...lld:pubmed
pubmed-article:8217588pubmed:authorpubmed-author:Vaughan...lld:pubmed
pubmed-article:8217588pubmed:authorpubmed-author:Vaughan...lld:pubmed
pubmed-article:8217588pubmed:issnTypePrintlld:pubmed
pubmed-article:8217588pubmed:volume68lld:pubmed
pubmed-article:8217588pubmed:ownerNLMlld:pubmed
pubmed-article:8217588pubmed:authorsCompleteYlld:pubmed
pubmed-article:8217588pubmed:pagination1006-11lld:pubmed
pubmed-article:8217588pubmed:dateRevised2009-11-18lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:meshHeadingpubmed-meshheading:8217588-...lld:pubmed
pubmed-article:8217588pubmed:year1993lld:pubmed
pubmed-article:8217588pubmed:articleTitleRisk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy.lld:pubmed
pubmed-article:8217588pubmed:affiliationDepartment of Epidemiology and Population Sciences, London School of Hygiene and Tropical Medicine, UK.lld:pubmed
pubmed-article:8217588pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8217588pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8217588lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8217588lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8217588lld:pubmed